Skip to content

Phase II Randomized Study of Stereotactic Radiosurgery Plus Fractionated Whole-Brain Radiotherapy Vs Fractionated Whole-Brain Radiotherapy Alone for Multiple Primary or Metastatic Brain Tumors

Status
UNKNOWN
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00004659
Enrollment
40
Registered
2000-02-25
Start date
1994-11-30
Completion date
Unknown
Last updated
2005-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brain Neoplasms

Keywords

adult brain tumor, brain tumor, childhood brain tumor, genetic condition, nervous tissue tumors, oncologic disorders, rare disease

Brief summary

OBJECTIVES: I. Evaluate whether stereotactic radiosurgery provides local control at multiple sites in patients with primary or metastatic brain tumors, controlled systemic disease, and preserved neurologic function. II. Examine survival, clinical outcome, and local tumor imaging response in these patients.

Detailed description

PROTOCOL OUTLINE: This is a randomized study. Tumor size and number are confirmed prior to randomization. Patients are stratified by participating institution. Patients are randomly assigned to 1 of 2 treatment groups. One group is treated with fractionated whole-brain irradiation using megavoltage equipment. The second group receives stereotactic radiosurgery plus fractionated whole-brain radiotherapy. Stereotactic radiosurgery involves irradiation of all tumors to the margins on stereotactic computerized tomography or magnetic resonance imaging. Either treatment may be administered first; the second treatment begins within 1 month of the first. Concurrent anticonvulsants and steroids are allowed. Patients are followed for change in size and number of tumors at 1, 3, and 6 months; follow-up clinical exams are performed at least every 2 months.

Interventions

PROCEDUREirradiation
PROCEDUREradiosurgery

Sponsors

University of Pittsburgh
CollaboratorOTHER
National Institute of Neurological Disorders and Stroke (NINDS)
Lead SponsorNIH

Study design

Allocation
RANDOMIZED
Primary purpose
TREATMENT

Eligibility

Sex/Gender
ALL
Age
0 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Multiple newly diagnosed brain tumors * Histologic confirmation of carcinoma at primary or metastatic site * Tumors less than 25 mm mean diameter and more than 5 mm from optic chiasm * No more than 4 tumors on magnetic resonance imaging * Systemic disease controlled * Neurologic function preserved * Radiographic staging within 2 months of randomization required * Performance status: Karnofsky 70%-100%

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026